Skip to main content

Table 6 Process and outcome indicators at baseline and follow-up for subgroups by gender, % (n/N)

From: Capacity building of health care professionals to perform interprofessional management of non-communicable diseases in primary care – experiences from Ukraine

Characteristica

Intervention

Control

Inter-action

 

Baseline

Follow-up

OR (95% CI)**

p-value**

Baseline

Follow-up

OR (95% CI)**

p-value**

p-value**

Women

 CVD patients

  Statin prescribed

39.1 (382/978)

54.6 (574/1051)

1.86 (1.56–2.22)

< 0.001

24.3 (78/321)

33.0 (107/324)

1.53 (1.08–2.16)

0.016

0.314

  HT drug prescribed

90.3 (883/978)

93.1 (978/1051)

1.43 (1.04–1.96)

0.029

81.0 (260/321)

86.1 (279/324)

1.43 (0.94–2.19)

0.096

0.959

  TC documented

33.5 (328/978)

60.2 (633/1051)

3.07 (2.56–3.69)

< 0.001

24.3 (78/321)

28.1 (91/324)

1.25 (0.87–1.78)

0.224

< 0.001

  TC at normal range

30.5 (100/328)

34.4 (218/633)

1.20 (0.90–1.60)

0.215

29.5 (23/78)

48.4 (44/91)

2.18 (1.15–4.15)

0.017

0.078

 HT patients

  HT drug prescribed

93.5 (1030/1102)

96.0 (1127/1174)

1.67 (1.15–2.44)

0.008

85.2 (339/398)

89.7 (366/408)

1.46 (0.95–2.23)

0.084

0.710

  BP control

15.2 (134/882)

12.1 (120/995)

0.77 (0.59–1.01)

0.055

10.4 (33/316)

13.2 (46/348)

1.32 (0.82–2.12)

0.255

0.054

 DM patients

  HbA1c documented

21.4 (49/229)

27.1 (71/262)

1.44 (0.95–2.20)

0.089

9.3 (5/54)

10.7 (9/84)

1.15 (0.36–3.65)

0.817

0.720

  FG documented

91.7 (210/229)

92.4 (242/262)

1.16 (0.60–2.25)

0.656

77.8 (42/54)

89.3 (75/84)

2.37 (0.92–6.12)

0.076

0.231

  TC documented

41.9 (96/229)

64.1 (168/262)

2.48 (1.72–3.57)

< 0.001

29.6 (16/54)

34.5 (29/84)

1.24 (0.59–2.60)

0.563

0.101

  Statin prescribed

49.8 (114/229)

59.2 (155/262)

1.45 (1.01–2.08)

0.043

24.1 (13/54)

32.1 (27/84)

1.52 (0.70–3.31)

0.291

0.924

  BP control

2.7 (6/226)

4.7 (12/258)

1.89 (0.70–5.14)

0.212

9.8 (5/51)

6.0 (5/84)

0.58 (0.16–2.12)

0.412

0.168

  FG control

35.2 (74/210)

40.5 (98/242)

1.20 (0.82–1.77)

0.352

47.6 (20/42)

44.0 (33/75)

0.89 (0.41–1.90)

0.755

0.484

  TC at normal range

29.2 (28/96)

30.4 (51/168)

1.01 (0.58–1.76)

0.979

12.5 (2/16)

37.9 (11/29)

4.36 (0.82–23.21)

0.085

0.089

Men

 CVD patients

  Statin prescribed

47.9 (395/825)

56.3 (502/891)

1.39 (1.15–1.69)

0.001

30.7 (79/257)

43.0 (120/279)

1.66 (1.16–2.37)

0.006

0.390

  HT drug prescribed

87.0 (718/825)

90.1 (803/891)

1.36 (1.01–1.83)

0.046

76.3 (196/257)

84.9 (237/279)

1.68 (1.08–2.61)

0.020

0.364

  TC documented

35.8 (295/825)

60.8 (542/891)

2.85 (2.34–3.47)

< 0.001

25.2 (65/257)

33.7 (94/279)

1.65 (1.12–2.42)

0.011

0.006

  TC at normal range

41.0 (121/295)

43.9 (238/542)

1.12 (0.84–1.50)

0.435

49.2 (32/65)

50.0 (47/94)

1.01 (0.54–1.91)

0.969

0.793

 HT patients

  HT drug prescribed

91.6 (846/924)

94.5 (924/978)

1.56 (1.09–2.24)

0.015

82.9 (271/327)

89.2 (313/351)

1.58 (1.01–2.47)

0.046

0.863

  BP control

14.8 (104/705)

15.6 (126/806)

1.08 (0.82–1.44)

0.578

9.6 (24/250)

13.8 (42/305)

1.53 (0.89–2.60)

0.122

0.254

 DM patients

  HbA1c documented

21.2 (33/156)

27.1 (52/192)

1.40 (0.84–2.31)

0.194

9.8 (5/51)

15.9 (11/69)

2.13 (0.67–6.80)

0.203

0.565

  FG documented

83.3 (130/156)

91.1 (175/192)

2.06 (1.07–3.95)

0.030

86.3 (44/51)

79.7 (55/69)

0.65 (0.24–1.78)

0.402

0.055

  TC documented

46.2 (72/156)

70.3 (135/192)

2.78 (1.78–4.32)

< 0.001

49.0 (25/51)

42.0 (29/69)

0.82 (0.39–1.73)

0.607

0.004

  Statin prescribed

57.7 (90/156)

62.5 (120/192)

1.22 (0.79–1.89)

0.361

31.4 (16/51)

43.5 (30/69)

1.62 (0.75–3.48)

0.222

0.578

  BP control

6.5 (10/153)

7.8 (15/192)

1.22 (0.53–2.80)

0.647

2.1 (1/47)

6.0 (4/67)

3.36 (0.35–32.02)

0.292

0.521

  FG control

38.5 (50/130)

38.9 (68/175)

1.02 (0.64–1.64)

0.925

47.7 (21/44)

40.0 (22/55)

0.76 (0.34–1.69)

0.496

0.425

  TC at normal range

41.7 (30/72)

34.1 (46/135)

0.72 (0.40–1.31)

0.283

36.0 (9/25)

27.6 (8/29)

0.62 (0.19–2.00)

0.420

0.873

  1. Abbreviations: CVD cardiovascular disease; HT hypertension; TC total cholesterol; BP blood pressure; DM diabetes mellitus; HbA1c glycated haemoglobin; FG fasting glucose; OR odds ratio; CI confidence interval
  2. aTC documented = Proportion of patients in the defined patient group with at least one documented total cholesterol measurement; Statin prescribed = Proportion of patients in the defined patient groups with stating prescribed; HT drug prescribed = Proportion of patients in the defined patient group prescribed blood pressure lowering drug; TC at normal range = Proportion of patients with cardiovascular disease whose last total cholesterol measurement was < 5 mmol/l; HT patients with BP control = Proportion of confirmed hypertensive patients whose last two blood pressure measurements were controlled (SBP < 140 mmHg and DBP < 90 mmHg), of which at least the most recent one during the last 12 months; DM patients with BP control = Proportion of diabetic patients whose last recorded blood pressure measurement was at normal range (systolic blood pressure < 130 mmHg and diastolic blood pressure < 80 mmHg); DM patients with FG control = Proportion of patients whose last fasting glucose measurement was < 7 mmol/l
  3. ** Age adjusted
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us